Early Detection | Kim Vanderlinden, CEO

(Transcription)

Kim Vanderlinden  0:01  

Hello. So I got into cancer or medicine because of my family. My mother died of lung cancer in her 50s. My only aunt, early 40s. My only cousin, breast cancer, late 30s. Oops, how do I get to dance?Oh, there we go. So the test we have is much more than a concept. We have over 20 clinical studies, seven countries, or 10,000 patients. Most importantly, you'll see in this talk, we it's not that we find cancer early, we can even detect precancerous tissue over 40% of the cancers, lung being the biggest and 20% of non smokers actually the inventor of the test, who's one of our founders of our company, his dad, his dad was a nonsmoker and died of lung cancer. In fact, one in four of us will be will be diagnosed with one of these cancers, one in four proximately 80 million Americans. How do our tests work? They're actually very, very simple. It's a complex technology, but we got it into a single strip point of care, you'll know within about 15 minutes, basically for the lung, all you have to do is cough up some sputum, put it on the stick, and it's like a pregnancy test and about 15 minutes. It's there's color, no color. Breast, you so you have to take a sample from each of the areas like a breast pump from nipple, aspirate, colon, rectal swab, prostate prosthetic fluid, and uterine cervical mucus, just like a second second pap smear. And again, it takes about 15 minutes to get this slide, you get the whole concept, understand how enormous and how significant this is. You can see in the in the piece of colon tissue, the cancer. And you can see to the right, well, it looks like normal tissue. Our marker is present away from the cancer as well. So you can see in this case, with the cancer, it tests positive. And it tests positive away from the from the tumor, healthy, healthy patients. The test negative so it's a our marker is a altered sugar in the intestine, or lung, prostate, etc. Here's a colon cancer trial. All the patients tested positive 100% sensitivity. So outstanding, almost 96% sensitivity or specificity. But this is there's a much bigger implication to this study. After removing the tumors 60 Go on to the next one. I need to go backwards 60% of the of the patients tested positive after the tumor was removed, tested positive. Within a year, there was a number of recurrences, so you can So what it's doing is it's finding the marker when the person is actually cancer free. The people that tested negative after having a cancer removed. No recurrences. We've had a similar with a similar trial with lung cancer. The opportunity is huge, of course, right one in four of us. A couple of the competitors liquid biopsies. They don't have the same sensitivity as lower sensitivity, which makes sense, because when there's a small small tumor, there's gonna be very little DNA in the blood. But one of them thrive sold for a couple billion 2020 GRAYL sold for 8 billion last year. So I love the liquid biopsies because they can screen for many cancers. But when it comes to the main cancers, the deadliest cancers. I think we need our test. Doctor, I know we need our test. Market potential for every 1% is over 300 million. And these are very conservative prices. We put a price of $195 for four tests for women. lung, breast, colon and lung and uterus, three for men lung, colon and prostate. My guess is the price of tests will be a bit higher. We want to keep them so everybody can afford them. But that's over 300 million for just 1%. The competition with lung, low dose CTS they still emit 40 radiation 14x Rays mammogram, for X rays, prostate, the PSA does not differentiate from enlarged prostate from a cancer. Whereas our test does. But when the prostate we've only done lab but in the lab, it completely differentiates perfectly between a cancer and enlarged prostate. Uterine, is a terrible void in medicine, there is no test for uterine cancer. Colon, I like to call a guard test. It's expensive and a lot of people don't want to it takes time to get your results back a couple of weeks, a week or a couple of weeks. Who wants to collect their own stool. And the liquid biopsies are limited again, the the limitation of them is a sensitivity for early stage cancers. When it comes to imaging tests, you can see you know, I showed you that on the intestine, a normal looking intestine you're not gonna be able to see it if precancerous. So imaging tests won't find it early stage. Same with a liquid biopsy is not enough DNA in the blood. One of the problems is with for instance, if he's find a very small mass. Typically we wait and see we can't biopsy all of those, because most of them are benign. So it would be great for physicians to know if there was an increased risk. If they did our test our screening tests ahead of time, they would know if those masses were increased chance of being cancerous. How would we use our funds, operational expenses, expand our executive team. Actually, last year was our first talk. And Scott Pentel who's the CEO here. He's now on the one of the advisors. So we're getting some great people. We're about to vote to launch. We have a lung trial scheduled for this fall. And we have breast and uterine central coming up soon. So we believe it's going to be at Stanford in a couple of months. So our advantages by far the biggest advantage we have is we find it early. An example is colon cancer stage 1, 95%, five year survival rates. Stage for a few years ago, it's only 5%. So the earlier you find a cancer, the greater the chances mean, our test is completely safe. It's a point of care, which is really nice for the physicians. The science, we've got over 20 studies, so it's affordable. The most important thing is we find it early. So we really we invite you to join us because we think this is a way we can reduce cancer mortality. Thank you and hope to see some of you in a few minutes.